BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23801168)

  • 1. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment.
    Brück A; Virta JR; Koivunen J; Koikkalainen J; Scheinin NM; Helenius H; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1567-72. PubMed ID: 23801168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.
    Lan MJ; Ogden RT; Kumar D; Stern Y; Parsey RV; Pelton GH; Rubin-Falcone H; Pradhaban G; Zanderigo F; Miller JM; Mann JJ; Devanand DP
    J Alzheimers Dis; 2017; 60(3):939-947. PubMed ID: 28984586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.
    Ossenkoppele R; Tolboom N; Foster-Dingley JC; Adriaanse SF; Boellaard R; Yaqub M; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):990-1000. PubMed ID: 22441582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.
    Li Y; Rinne JO; Mosconi L; Pirraglia E; Rusinek H; DeSanti S; Kemppainen N; Någren K; Kim BC; Tsui W; de Leon MJ
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2169-81. PubMed ID: 18566819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
    Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
    Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI.
    Kemppainen NM; Scheinin NM; Koivunen J; Johansson J; Toivonen JT; Någren K; Rokka J; Karrasch M; Parkkola R; Rinne JO
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):283-9. PubMed ID: 24072346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment.
    Zhang S; Han D; Tan X; Feng J; Guo Y; Ding Y
    Int J Clin Pract; 2012 Feb; 66(2):185-98. PubMed ID: 22257044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis.
    Fu L; Liu L; Zhang J; Xu B; Fan Y; Tian J
    Eur Radiol; 2014 Nov; 24(11):2800-9. PubMed ID: 25097125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.
    Ito H; Shinotoh H; Shimada H; Miyoshi M; Yanai K; Okamura N; Takano H; Takahashi H; Arakawa R; Kodaka F; Ono M; Eguchi Y; Higuchi M; Fukumura T; Suhara T
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):745-54. PubMed ID: 24233004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
    Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.